Aim: New epigenetically based methods for assessing risk for coronary heart disease may
be more sensitive but are generally more costly than current methods. To understand their
potential impact on healthcare spending, we conducted a cost–utility analysis. Methods:
We compared costs using the new EpiÂ+ Â Gen CHDâ „¢ test with those of existing tests
using a cohort Markov simulation model. Results: We found that use of the new test was
associated with both better survival and highly competitive negative incremental …

Background Coronary heart disease (CHD) is associated with over 350,000 deaths and
750,000 heart attacks annually. Current CHD risk estimators such as the Framingham Risk
Score and Pooled Cohort Equation (PCE) lack sensitivity and generalizability. Epi+ Gen
CHD is a new integrated genetic-epigenetic three-year risk estimator for incident CHD that is
highly sensitive for both men and women. We conducted cost-utility analyses to understand
the potential impact of Epi+ Gen CHD on healthcare spending. Methods A Markov model …